Share ideas that matter on the social web and experience
the benefits of curating the world's best content.
I don't have a Facebook, a Twitter or a LinkedIn account
|
Scooped by Julien Hering, PhD onto Pharmaceutics_R&D |
Scoop.it!
In another move that will worry multi-national drugmakers, India is looking to widen price controls to extend beyond generics to include branded drugs that are imported into the country, according to reports. The effort comes as the global pharmaceutical industry closely watches how the Indian government guards patent protection, an issue that is currently playing out in two controversial court cases. (...) - by Ed Silverman, Pharmalot, September 6th, 2012
Are you sure you want to delete this scoop?
 Your new post is loading...
Scoop.it!
Le Tour de France de LaBiotech à vélo vise à réaliser un panorama filmé des entreprises de biotechnologies pour le partager au monde entier. Nous sommes les co-fondateurs du site LaBiotech.fr qui centralise l’actualité des Biotechnologies tout en créant du contenu exclusif pour vous informer du secteur rapidement, simplement et gratuitement. Lancé en décembre 2012, il rassemble désormais plus de 300 abonnés et 2000 visiteurs uniques. Avec deux vélos, nos jambes et du soutien, nous souhaitons parcourir la France pour interviewer les différentes entreprises des Biotechnologies. Le trajet et les interviews, tous les deux filmés, seront rassemblés dans un documentaire sous-titré en anglais, allemand et espagnol. Le but étant d'établir un panorama du secteur des biotechnologies françaises et de le partager gratuitement avec le monde entier. Le Tour débutera par un prologue en Ile de France du 1er au 12 juillet et partira de Paris le dimanche 14 juillet jusqu'au vendredi 2 aout. Les grandes destinations seront Strasbourg, puis Lyon, Marseille, Bordeaux et Nantes. Pour réaliser ce tour, nous avons besoin d'un budget de 4000€ composé de matériel photo/vidéo, de matériel vélo et des frais de déplacement. Nous avons besoin de vous pour nous aider et permettre de réaliser cette expérience qui sera positive pour le secteur des biotechnologies françaises ainsi que pour la France. Ce projet vous plait ? Alors suivez-nous, partagez-nous et soutenez-nous ! Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Baisses de prix, impact des génériques : le marché du médicament devrait continuer de décliner cette année en France, selon une étude d’IMS Health. Une embellie serait possible en 2014, en fonction des décisions politiques. Alors que les plans sociaux se poursuivent dans l’industrie pharmaceutique, les perspectives sur le marché français sont toujours sombres. Après avoir connu la première récession de son histoire en 2012, avec une chute de 2,3% en valeur, le marché des médicaments en ville devrait s’effondrer de 3,4% cette année, selon l’étude présentée ce mardi par le cabinet de conseil pour les acteurs de la santé IMS Health. (...) L'Usine Nouvelle, par Gaëlle Fleitour, 19 mars 2013 Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
AstraZeneca a lancé Bipolife® : le premier outil interactif à visée psychoéducative spécifiquement dédié aux troubles bipolaires. Développé en collaboration avec l’entreprise Ubisoft et sous la supervision d’un comité scientifique, Bipolife® a pour objectif d’aider les personnes souffrant de troubles bipolaires à mieux comprendre leur maladie et à identifier les comportements quotidiens qui influent sur son évolution. (...) - MyPharma, 01/04/2013 Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
The government wants to make all publicly funded research available – but the same must be demanded of pharmas also I recently had lunch with as staunch an advocate for open access as you'll ever meet (I won't name him, because it would be rude to attribute casual remarks to him without permission). We were talking about plans to mandate free and open publication of publicly funded scientific research. In the USA, there's the Federal Public Research Act, and in the UK, there's the coalition government's announcement that publicly funded research should be made available at no cost, under a Creative Commons licence that permits unlimited copying. (...) by Cory Doctorow, The Guardian, 20 november 2012 Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Background: Due to the declining innovativeness of the classic R & D model in the original pharmaceutical industry, the generic pharmaceutical industry is aiming to become an innovation generator itself. Results: Those generic pharmaceutical firms that implement new competitive strategies have integrated re-innovation design into their product portfolio to provide more personalized, cost-effective products to meet the healthcare systems’, policymakers’ and patients’ demand for high quality accessible treatments. This re-orientation hopes to better face the changing competition challenges in both mature and developing markets. (...) - by Barei F. et al., Generics and Biosimilars Initiative Journal (GaBI Journal). 2013;2(1) Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Biogen Idec's BG-12, United Therapeutics' oral Remodulin, Johnson & Johnson's Invokana and Allergan's Levadex are all nearing their possible launches Investing in drug stocks isn't quite like investing in other stocks. While drugmakers' shares can move on earnings and buyout news like anyone else's, what really gets investors excited is an FDA decision allowing a new drug on the market. Here are some of the most important drugs awaiting approval in the next month. (...) - by Amy Reeves, Investors.com, 03/15/2013 Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Parmi les Big Pharma, Johson&Johson est la seule survivante dans le TOP60 des « most visible companies » établi tous les ans par Harris, avec une excellente 5e place. Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Biomedical research and innovation are crucial to improving America’s health, global competitiveness, and economic growth, as both President Obama and House Majority Leader Cantor have stressed in recent weeks. In the wake of the sequester, and as the President and Congress move ahead with budget negotiations, now is the time for both parties to translate into action their bipartisan commitment to our nation’s science investment by restoring the budgets of the National Institutes of Health (NIH) and other science agencies that support basic biomedical research in universities and medical schools in all 50 states – an area of federal spending that is highly productive and a critical investment. (...) - by Marc Tessier-Lavigne, President, The Rockefeller University and former Chief Scientific Officer, Genentech Inc. (left); P. Roy Vagelos, Chairman, Regeneron Pharmaceuticals, and Retired Chairman and CEO, Merck & Co., Inc. (center); and Elias Zerhouni, President R&D Sanofi and former Director of the National Institutes of Health., Forbes, 03/06/2013 Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Le groupe pharmaceutique allemand Grünenthal et Ethypharm, société française spécialisée dans les technologies de formulation innovantes, ont conclut un accord de licence, de distribution et d’approvisionnement exclusif. Cet accord permet à la société de commercialiser les comprimés sublinguaux à base de fentanyl d’Ethypharm pour le traitement des accès de douleur dus au cancer sur des marchés européens sélectionnés. (...) MyPharma Editions, 06/03/2013 Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
UCB chief executive Roch Doliveux has attacked the idea of making all clinical trial data publicly available, saying it could be ‘dangerous and misleading’. (...) - by Adam Hill, Pharmafile via PharmaGossip, 27/02/2013
Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Proponents hope consortium will revive flagging industry. Two sites shuttered by the pharmaceutical giant Merck, one in Scotland and one in the Netherlands, will soon be humming again with the work of drug discovery. But the hum will not be business as usual. It will be the sound of a public–private consortium placing a high-stakes wager: a nearly €200-million (US$271-million) bet that it can boost a languishing pharmaceutical sector by fusing academic innovation with industrial-scale screening, using robots to test chemicals for biological activity. (...) - by Monya Baker, Nature, 07 February 2013 
James A Smith MCIM's curator insight,
February 25, 7:17 AM
Some big money investment here and interesting to see from a business model perspective Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Who in this business hasn't seen billions incinerated in pursuit of sheer folly? Influence is a fungible asset. A lot of cash on hand can help tremendously, of course. But at this stage, who in this business hasn't seen billions incinerated in pursuit of sheer folly? Far more influential is the savvy executive who can marshal experts as well as financial resources in pursuit of a smarter, better, faster way to develop and market important new drugs. (...) - by John Carroll, FierceBiotech Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Biopharmaceutical companies are touting their huge investment in R&D, which has filled the drug pipeline with more potential first-in-class medicines, including orphan drugs, personalized medicines and new therapies based on novel scientific strategies. A report by the Analysis Group for the Pharmaceutical Research and Manufacturers of America (PhRMA) documents more than 5,000 new medicines in the pipeline globally, many for untreated diseases and life-threatening conditions. The promise is that this more robust pipeline will lead to more new critical therapies for patients. Yet, the data also reveals that most of these therapies are in early stages of development: less than 1000 of the 5400 products in clinical development have reached stage III, and only 82 are headed for market following approval by the Food and Drug Administration. The attrition from phase II to phase III remains very high despite a range of scientific advances and regulatory improvements. Of nearly 3000 new molecular entities (NMEs) to treat cancer, only 288 have reached stage III clinical trials, and only a handful make it to market. Therapies for infectious diseases seem to have a higher success rate, with about 700 investigational projects yielding 22 recent approvals. Certainly a higher “early kill” rate may be a sign of progress in the risky world of pharma R&D, where a key goal is to avoid costly phase III studies that won’t pass muster with FDA. The current study doesn’t provide the historical data that could tell more about whether pharma R&D is becoming more productive, but there doesn’t seem to much evidence of progress. A more telling sign is the recent rise in FDA’s approval numbers for NMEs, reaching almost 40 in 2012 and still providing steady good news for sponsors. The promise is that more INDs eventually will yield more new approved medicines. “There are no guarantees” from a stronger and more diverse pipeline, but the study reveals the “depth of possibilities,” observed Genia Long of the Analysis Group in a PhRMA webinar. However, it also is important for pharma to reduce the overall cost of developing new drugs, and that will require more informative early stage research strategies that efficiently separate potential winners from likely losers. Researchers are making progress in developing treatments for Alzheimer’s disease, pointed out Eli Lilly CEO John Lechleiter, acknowledging that success “will require longer, more expensive studies to show benefit for patients.” The PhRMA report aims to demonstrate to the public and policymakers the high value of biopharmaceutical R&D and the importance of continuing government support for FDA programs and research funded by the National Institutes of Health. It also highlights the value – and the need to pay for – new therapies to treat rare diseases and conditions that currently lack effective treatment. Ultimately, these new, costly research endeavors could lead to cures and preventives for cancer, Alzheimer’s and other devastating illnesses that affect millions. But the costs for individual patients may be enormous, and it remains to be seen if public and private health programs will pay for them.
Via Lionel Reichardt / le Pharmageek, Chaturika Jayadewa Delete the scoop?
Are you sure you want to delete this scoop?
Yes
|
Scoop.it!
Which company takes the title? It may come as no surprise that pharma giant Pfizer claims the lead spot, however the sequence that follows shows interesting trends. In this article I’ll share bioscience companies with ideal digital presence and touch on available apps to score yours. The performance indictor was the Bio Web Score Absolute, a free tool measuring the digital presence of life science businesses. (...) - Biowebspin Public Place, by Sara Ahmadi, 26/04/2013 Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
A la recherche du ePatient. (RT @laumacom: A la recherche du ePatient. http://t.co/Nv8KD0FUnr (via @pharmacomptoir) #ePatient #esante) Via Pharmacomptoir / Corinne Thuderoz Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
ClassroomWindow™: Providing an unprecedented view into what works - and for which kids - in U.S. classrooms.
Via Marcel Lebrun 
vgpascal's curator insight,
April 14, 1:55 AM
Les effets des classés inversées sur l'apprentissage et sur la satisfaction de "donner des occasions d'apprendre" ;-) 
Matthieu CLEMENT's comment,
April 17, 12:58 AM
Cette méthode marche très bien dans le cadre de l'université. Pour l'avoir testé en classe de seconde en France, c'est beaucoup plus difficile dans le secondaire. http://aggiornamento.hypotheses.org/1238
Bernard Buchel's curator insight,
April 21, 7:58 AM
Marcel Lebrun souligne : "De meilleures attitudes des étudiants, des enseignants davantage satisfaits, de meilleurs scores (standardisés) aussi aux évaluations. Pour ce dernier point, tout dépend de ce que l'on "mesure" mais en tout cas, pas de perte dans les connaissances ( les savoirs) contrairement à ce que pourraient penser les grognons. Il faudrait faire de cette méthode une priorité institutionnelle !" Bref il n'y a pas que les techniques numériques pour renouveler la pédagogie. Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
European agency will publish firms’ clinical-trial results. International calls for the pharmaceutical industry to share the results of clinical trials have grown ever more intense amid revelations that high-profile companies have hidden crucial data on safety and efficacy. Now Europe is moving towards measures that would significantly increase disclosure of such data. (...) - by Daniel Cressey, Nature, 27 March 2013 Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
US biopharmaceutical companies are currently developing 465 new medicines that target the 10 leading chronic conditions affecting people aged 65 and over, according to new industry data. The medicines, which are all now in clinical trials or under review by the Food and Drug Administration (FDA), are diverse in scope, notes the Pharmaceutical Research and Manufacturers of America (PhRMA), which has published the data. (...) - by Lynne Taylor, PharmaTimes, March 22, 2013 
NCTC's curator insight,
March 29, 4:19 AM
Interesting, also in light of the Dutch IEMO project which aims at including seniors in clinical trials to measure the effect durgs have have on them. Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
A major reorganization of its research operations will result in 1,600 jobs being cut by AstraZeneca, with roughly 650 positions slashed in the U.S. (...) - By Russ Britt, MarketWatch blog "Health Exchange", March 18, 2013 Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Many drug-makers hope to recruit in next few years. Many biopharmaceutical companies plan to hire scientists in the next three years, according to a report published on 4 February by the PwC Health Research Institute in Washington DC, part of London-based professional-services firm PwC. New Chemistry: Getting the Biopharmaceutical Talent Formula Right, which is based on surveys of company executives and recruiters, finds that 72% of drug-makers plan to boost their research capacity in the next 12 months by hiring scientists, creating partnerships or improving infrastructure. The results of the survey suggest that jobs will grow by about 30% among US medical scientists, biochemists and biophysicists by 2020. Responding companies want recruits who can develop and manage external partnerships, and who know about regulatory science, bioinformatics and outcomes research. Early-career scientists looking for opportunities need to “think about the entire value chain that leads to the development of a drug or medical device”, says Christopher Khoury, a senior manager at the Health Research Institute and lead author of the report. - Nature 494, 509 (2013), Published online 27 February 2013 Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Big pharma needs to change its whole business model. The business model for large pharmaceutical companies hasn't changed for decades. You target a huge population, like people with heart disease, find and patent a drug that's at least marginally better than current treatments, and make billions. It's worked pretty well for a long time. (..) - by Max Nisen, Business Insider, Mar. 4, 2013 Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
BALLERUP, Denmark and PLANEGG-MARTINSRIED, Germany , Feb. 26, 2013 /CNW/ - LEO Pharma A/S, a global pharmaceutical company specialising in dermatology, has entered into an exclusive research and license agreement with the German biotech company 4SC Discovery GmbH with the primary aim of jointly researching, developing and commercialising an oral treatment for inflammatory skin diseases such as psoriasis. (...) - biospace.com, 02/26/2013 Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
La chute de l’emploi dans le secteur pharmaceutique n’est pas inexorable, estiment les industriels. Chiffres à l’appui, ils ont dégagé les leviers à actionner pour limiter la casse sociale. (...) - Par Gaëlle Fleitour, L'Usine Nouvelle, 23 janvier 2013 Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
This article is about promotional compliance trends in Europe following the lead of anti-bribery and anti-corruption laws set in the United States. In this article, we look at European pharma promotional compliance trends as reported in Cegedim Relationship Management’s third annual survey: ‘2012 European Trends in Aggregate Spend, Transparency, and Disclosure’. The pharmaceutical, medical device and biotech industries are currently witnessing the rise of tighter promotional transparency regulations. As many expected, the stringency of anti-corruption and anti-bribery laws already in place in the United States are beginning to make their way over to Europe, with some countries in Europe already surpassing the enforcement levels set by the US. (...) - by Hannah Blake, pharmaphorum, 5th February 2013 Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
File this under ‘sad irony.’ Now that the pharmaceutical industry has tossed thousands of people overboard during the last decade – an estimated 150,000 or so just since 2009 – a slight majority of drugmakers complain that it has become increasingly difficult to find the right talent and most worry they will not have access to the people they need to hire, according to a report from PricewaterhouseCoopers. (...) - By Ed Silverman, Pharmalot, February 5th, 2013 Delete the scoop?
Are you sure you want to delete this scoop?
Yes
|
